PSD2: A Potential Drug Target and Biomarker (G84249)

Target Name: PSD2

NCBI ID: G84249

PSD2: A Potential Drug Target and Biomarker

Introduction

PSD2 (Protein-Protein interactions Domain 2) is a gene located on chromosome 13q32. It is a non-coding RNA molecule that plays a crucial role in the regulation of protein-protein interactions, which are the foundation of many cellular processes. The study of protein-protein interactions has led to the identification of numerous drug targets and biomarkers. PSD2 is one of these targets, which has great potential in the development of new therapeutics for various diseases.

PSD2: Structure and Function

PSD2 is a small non-coding RNA molecule that contains 29 amino acid residues. It is characterized by a long N-terminus, a single AUG Start codon, and a C-terminus that contains a conserved GCA sequence. PSD2 is primarily expressed in the brain, heart, and pancreas, and its levels are highly dependent on the stage of development and the presence of neurotransmitters.

PSD2 functions as a negative regulator of protein-protein interactions by binding to protein-protein interaction domains (PPIDs) in target proteins. This interaction between PSD2 and PPIDs results in the inhibition of protein-protein interactions, thereby modulating the activity of these interactions. This mechanism of action is similar to that of other RNA molecules that act as negative regulators, such as RNA-protein interaction blockers (RISCs) and small RNA domains (SRIs).

PSD2 as a Drug Target

PSD2 has been identified as a potential drug target due to its involvement in protein-protein interactions. Many diseases are caused by the disruption of protein-protein interactions, which can lead to the misfolding of proteins and the formation of aggregates that contribute to the development of diseases such as Alzheimer's, Parkinson's, and huntingtin-induced diseases. Therefore, targeting PSD2 and modulating its activity may be a promising strategy for the development of new therapeutics for these diseases.

PSD2 has been shown to play a role in the development and progression of several diseases, including Alzheimer's disease, Parkinson's disease, and huntingtin-induced diseases. For example, studies have shown that PSD2 is overexpressed in the brains of individuals with Alzheimer's disease and that this overexpression is associated with the development of neurofibrillary tangles and the loss of cognitive function. Similarly, PSD2 has been shown to be overexpressed in the brains of individuals with Parkinson's disease and is associated with the development of neurodegeneration and the loss of motor function.

PSD2 has also been shown to play a role in the development of huntingtin-induced diseases, which are a group of rare genetic disorders that are characterized by the expression of huntingtin, a protein that is often misfolded and forms aggregates. Studies have shown that PSD2 is involved in the regulation of huntingtin stability and that its activity is disrupted in individuals with huntingtin-induced diseases.

PSD2 as a Biomarker

PSD2 has also been shown to be a potential biomarker for several diseases, including Alzheimer's disease, Parkinson's disease, and huntingtin-induced diseases. The levels of PSD2 have been shown to be altered in individuals with these diseases, and these changes have been associated with the disruption of protein-protein interactions.

For example, studies have shown that the levels of PSD2 are elevated in the brains of individuals with Alzheimer's disease, and this increase in PSD2 is associated with the development of neurofibrillary tangles and the loss of cognitive function. Similarly, PS

Protein Name: Pleckstrin And Sec7 Domain Containing 2

More Common Targets